Autoantibodies, Complement and Type I Interferon as Biomarkers for Personalized Medicine in SLE

Lupus - United Kingdom
doi 10.1177/0961203316640922
Full Text
Abstract

Available in full text

Categories
Rheumatology
Date
Authors
Publisher

SAGE Publications

Related search

Circulating miRNAs as Potential Biomarkers in Myasthenia Gravis: Tools for Personalized Medicine

Frontiers in Immunology
AllergyImmunology
2020English

123 Mir-127–3p as a Novel Regulator of Type I Interferon Signalling Pathway in Sle

2017English

Personalized Medicine in Diabetes: The Role of ‘Omics’ and Biomarkers

Diabetic Medicine
Internal MedicineEndocrinologyMetabolismDiabetes
2016English

Autoantibodies as Potential Biomarkers in Breast Cancer

Biosensors
MedicineClinical Biochemistry
2018English

Discovery of Novel Biomarkers for the Development of Personalized Medicine

Translational Medicine
2012English

101 Gilz Represents a Checkpoint Limiting Cyclical Exacerbation of Inflammation in Sle by Type I Interferon

2017English

Aberrant Type I Interferon Regulation in Autoimmunity: Opposite Directions in MS and SLE, Shaped by Evolution and Body Ecology

Frontiers in Immunology
AllergyImmunology
2013English

Anti-NT5c1A Autoantibodies as Biomarkers in Inclusion Body Myositis

Frontiers in Immunology
AllergyImmunology
2019English

Autoantibodies as Diagnostic Biomarkers for Lung Cancer: A Systematic Review

Cell Death Discovery
Cancer ResearchMolecular NeuroscienceImmunologyCell BiologyCellular
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy